Valuation: Bio-View Ltd

Market Cap 10.04M 0 3.33M 2.9M 2.73M 2.49M 4.67M 319M 4.67M 32.73M 12.62M 162M 12.5M 12.23M 524M P/E 2024
-11.7x
P/E 2025 -1.48x
Enterprise Value 5.61M 0 1.86M 1.62M 1.53M 1.39M 2.61M 178M 2.61M 18.3M 7.05M 90.81M 6.99M 6.83M 293M EV / Sales 2024
1.04x
EV / Sales 2025 0.9x
Free-Float
48%
Yield 2024 *
-
Yield 2025 -
1 day-5.43%
1 week-7.19%
Current month-6.49%
1 month-10.30%
3 months-33.24%
6 months-52.59%
Current year-55.15%
1 week 71
Extreme 71
82
1 month 71
Extreme 71
84.5
Current year 71
Extreme 71
294
1 year 71
Extreme 71
294
3 years 71
Extreme 71
370
5 years 71
Extreme 71
480
10 years 71
Extreme 71
515
Manager TitleAgeSince
Corporate Officer/Principal 64 2009-03-21
Director of Finance/CFO 44 2020-11-30
Chief Operating Officer 49 2010-12-31
Director TitleAgeSince
Chairman 87 2000-03-15
Director/Board Member 63 2015-05-31
Director/Board Member 70 2022-06-27
Change 5-day change 1-year change 3-year change Capi.($)
-5.43%-7.19%-60.58%-76.82% 3.33M
-0.04%+4.11%+18.45%-21.86% 17.7B
+2.92%+9.61%-38.92%+47.27% 1.94B
+0.04%+1.47%-31.54%+25.57% 887M
-0.11%+0.05%+50.41%-0.38% 778M
+2.26%-2.34%-62.27%-84.88% 745M
+3.27%+3.66%-33.47%-47.58% 663M
+3.33%+0.46%-41.71%-52.96% 574M
-14.79%-12.01%-52.70%-46.75% 438M
+3.32%+11.82%+49.04%+81.33% 450M
Average -0.52%+1.96%-20.33%-17.71% 2.42B
Weighted average by Cap. +0.23%+7.21%+6.97%-15.80%

Financials

2024 2025
Net sales 25.66M 0 8.51M 7.42M 6.99M 6.36M 11.93M 815M 11.94M 83.67M 32.25M 415M 31.96M 31.25M 1.34B 19.93M 0 6.61M 5.76M 5.43M 4.94M 9.27M 633M 9.28M 65M 25.05M 323M 24.83M 24.28M 1.04B
Net income -3.15M -0 -1.04M -910K -857K -781K -1.46M -100M -1.47M -10.27M -3.96M -50.95M -3.92M -3.83M -164M -15.33M -0 -5.08M -4.43M -4.18M -3.8M -7.13M -487M -7.14M -50M -19.27M -248M -19.1M -18.68M -801M
Net Debt -8.96M -0 -2.97M -2.59M -2.44M -2.22M -4.17M -285M -4.17M -29.22M -11.26M -145M -11.16M -10.91M -468M -4.43M -0 -1.47M -1.28M -1.21M -1.1M -2.06M -141M -2.06M -14.43M -5.56M -71.63M -5.51M -5.39M -231M
Logo Bio-View Ltd
Bio-View Ltd. is an Israel-based company that operates within the medical devices industry. The Company focuses on developing, manufacturing, and marketing automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories. One of the key products offered by the Company is the Accord Plus. This product is an automatic fluorescent imaging system that scans, analyzes, and sorts a range of Fluorescence In Situ Hybridization (FISH) and karyotype samples in real-time. The primary goal of this technology is to facilitate the identification of various chromosomal aberrations, such as amplifications, translocations, inversions, and deletions, under fluorescent light.
Employees
30
Date Price Change Volume
26-09-17 ILA 74.90 -5.43% 9,296
26-09-16 ILA 79.20 +0.13% 111
26-09-15 ILA 79.10 -1.98% 7,356
  1. Stock Market
  2. Stocks
  3. BIOV Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!